US-based molecular diagnostic company Diagnovus has introduced a gene expression assay for patients with diffuse large B-cell lymphoma (DLBCL), a cancer of B cells.
Combining a patient’s International Prognostic Index (IPI) score and the results, the Engauge-cancer-DLBCL assay studies underlying tumor biology of patients, and allows physicians to make more informed treatment decisions.
Stanford University School of Medicine lymphoma programme leader Dr Ron Levy said traditional stratification schemes based on clinical characteristics such as the IPI have provided prognostic guidance in the management of patients with DLBCL.
"Despite the ease of use, IPI does not fully capture disease heterogeneity, and it is common to have two patients with identical IPI risk scores have very different outcomes," Levy said.
University of Miami lymphoma head Dr Izidore Lossos said; "Knowledge of molecular prognostic markers may identify cellular mechanisms leading to the recognition of specific molecular targets for new therapeutic approaches."
Unlike other genome-based assays, which require special handling such as snap freezing in liquid nitrogen, the molecular diagnostic Engauge-cancer-DLBCL test uses routinely available formalin-fixed, paraffin-embedded (FFPE) diagnostic biopsy tissue and performs the assay in a reproducible and accurate manner, according to the company.
Diagnovus vice president and co-founder Dr James STOVER said the company’s mission is to develop molecular diagnostic assays that facilitates physicians to achieve better outcomes for patients.
"Using well-studied genes incorporated into a multiplexed panel,Engauge-cancer-DLBCL has been developed from more than 10 years of research and exceeds the standard clinical characteristics that clinicians have used for prognosis for the last three decades," Stover said.